CA2189140C - New antagonist compounds - Google Patents

Abstract

New morphinane derivatives of formula (I), their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.

Description

~

WO 95131463 ~ ~ PC17SE95100503 NEW ANTAGONIST COMPOUNDS
Field of the invention The present invention is related to novel 8 opioid receptor antagonists as well as to their pharmaceutically acceptable salts, a process for their preparation and their use in the manufacture of pharmaceutical preparations.
Backl;round of the invenr;~n Opiod antagonists have been indispensable as tools in opioid research. For example, the chief criterion for the classification of an agonist effect as being opioid receptor mediated is the ability of known opioid antagonists naloxone or naltrexone to reversibly antagonize this effect in a competitiv a fashion. The usefulness of naloxone and naltrexone for this purpose stems from the fact that they are universal opioid antagonists; that is, they are capable of antagonizing the agonist effects mediated by multiple opioid receptor types.
Since it is now firmly established that there are a minimum of three opioid receptor types (~,, x and 8), it has become increasingly evident that selective opioid antagonists are valuable pharmacological tools for identifying receptor types involved in the interaction with opioid agonists. One of the major advantages of selective opioid antagonists over selective agorusts is their utility in probing the interaction of endogenous opioid peptides and new opioid agonists with opioid receptor types. Moreover, since it is sometimes not easy to distinguish among ~, x and 8 opioid receptor mediated agorust effects if the pharmacological endpoints are identical (e.g. antinociception or inhibition of a smooth muscle preparation by agonists), selective antagonists clearly have wider utility as tools than selective agorusts.

~I~g~~O
W095/314G3 '~, s, :~E j' ~ PCTlSE951005113 The general utility of selective antagonists as pharmacological tools depends upon the correlation of in vitro and in vivo acitivity. This can be accomplished more easily with non-peptide ligands because they generally can penetrate the blood-brain barrier and therefore can be administered peripherally in vivo. Also, they are less subject to metabolism than are peptides.
In addition to their uses as pharmacological tools, selective, non-peptide opioid antagonists have been described as having potential clinical applications in the treatment of a variety of disorders where endogenous opioids play a modulatory role. These include for instance disorders of food intake, shock, constipation, mental disorders, CNS injury, alcoholism, and immune function (immune stimulation or suppression) (P.S. Portoghese et al., J. Med. Chem., Vol 34:

1762, 1991).
Non-peptide, competitive, b-selective opioid antagonists have been found recently. The prototypes are: cyprodime for It (H. Schmidhammer et al., J.
Med.
Chem., Vol. 32:418-421,1989; H. Schmidhammer et al., J. Med. Chem., Vol. 33:
1200-1206,1990), norbinaltorphimine for x (1'. S. Portoghese et al., J. Med.
Chem., Vol. 30:238-239,1987), and naltrindole for b opioid receptors (P.S. Portoghese et al., J. Med. Chem., Vol. 31:281-282,1988).
These compounds (cyprodime, norbinaltorphinine and naltrindole) are being used as pharmacological tools. They have been tritium labelled and can be used as receptor selective ligands in opioid receptor binding studies to sort out the affinities of new ligands to different receptors and to determine whether a compound is selective to a special receptor.
An object of the present invention was to find new, highly selective 8 opioid receptor antagonists with high potency. Another object was to find highly selective b opioid receptor antagonists with high immunosuppressive potency.
The high selectivity for b opioid receptors would repress adverse side effects ~~~~~Q
WO 95!31463 PCTISE95100503 caused by the interaction with other receptors. Still another object was to find compounds which have a brain-cell protecting effect. The problem with the 8 opiod receptor antagonists known from the prior art is that they are not highly selective.
Prior ar Certain opioid agorusts represented by morphine, which act on It receptors, are known to exhibit immunosuppressive effects. The agonist enkephalin, which acts on 8 opioid receptors, exhibit immunostimulating effects (Plotnikoff, Enkephalins and Endorphins, Stress and Immune System, Plenum Press, I986). Although a number of reports have been issued concerning the immunosuppressive effects of agorusts of ~ receptors, it is difficult to develop an immunosuppressive agent by employing an agonist of ~t receptors, since such agonists show critical side effects such as addiction, respiratory depression, constipation etc.
Recently it has been reported that S-selective opioid antagonists have immunosuppressive effects. See EP 456 833, EP 485 636 and EP 614 898.
Outline of the invention The present invention provides novel compounds of the formula (I) wherein R~ represents Cz-Clo alkenyl; C4-Coo cycloalkylalkyl wherein the cycloalkyl is C3-C~
cydoalkyl and the alkyl is C~-C4 alkyl; C4-Coo cykloalkenylalkyl wherein the cydoalkenyl is C3-C6 cykloalkenyl and the alkyl is C~-C~ alkyl; C~-C16 arylalkyl wherein the aryl is C6-C1o aryl and the alkyl is C1-C6 alkyl; Ce-C~6 arylalkenyl wherein the aryl is C6-Cto aryl and the alkenyl is C~-C6 alkenyl;
Rz represents hydrogen, hydroxy, C~-C6 alkoxy; Cz-C6 alkenyloxy; C~-C~6 arylalkyloxy wherein the aryl is C6-Coo aryl and the alkyloxy is C~-C6 allcyloxy; C~
Cl6 arylalkenyloxy wherein the aryl is C6-Coo aryl and the alkenyloxy is Cz-C6 alkenyloxy; C~-C6 alkanoyloxy; C;-C16 arylalkanoyloxy wherein the aryl is C6-Coo aryl and the alkylaroyloxy is C~-C6 alkylaroyloxy;
R3 represents hydrogen, C~-C6 alkyl; Cz-C6 alkenyl; C~-Cl6 arylalkyl wherein the aryl is C6-Coo aryl and the alkyl is C~-C6 alkyl; C~-C~6 arylallcenyl wherein the aryl is C6-Coo aryl and the alkenyl is Cz-C6 allcenyl; hydroary(C~-C6)alkyl;
alkoxyalkyl wherein the allcoxy is C~-C6 alkoxy and the alkyl is C~-C6 alkyl; COzI-i;
COi(C~-C6 alkyl);
R~ is hydrogen, hydroxy; C~-Ca alkoxy; C~-C,6 arylalkyloxy wherein the aryl is~Cb Coo aryl and the alkyloxy is C~-C6 alkyloxy; Cz-C6 alkenyloxy; C~-C6 alkanoyloxy;
C~-C16 arylalkanoyloxy wherein the aryl is C6-Coo aryl and the alkanoylo~cy is Ci C6 alkanoyloxy; C~-Coo alkyloxyalkoxy wherein alkyloxy is Cl-C; alkyloxy and alkoxy is C~-C6 allcoxy;

R3 and R6 each independently represent hydrogen; OH; C~-Cb alkoxy; C~-C6 alkyl;
hydroxyalkyl wherein the alkyl is C~-C6 alkyl; halo; vitro; cyano;
thiocyanato;
trifluoromethyl; COzH; COI(C~-C6 alkyl); CONH=; CONH(C~-Cb alkyl); C0~1(C~-C6 alkyl)2; amino; C~-C6 monoalkyl amino; C1-C6 diallryl amino, Cs-C6 5 cydoalkylamino; SH; S03H; S03tC~-C6 alkyl); SOz(C~-C6 alkyl); SO
SOzNH(C1-C6 alkyl): SO=NH (C?-C16 arylalkyl); SOtC~-C6 alkyl); or RS and R6 together form a phenyl ring which may be unsubstituted or substituted by halo, vitro, cyano, thiocyanato; C~-C6 alkyl; trifluoromethyl; C~-C6 alkoxy, CO~i, CCKC~-C6 aUcyl), amino, C~-C6 monoalkylamino, C~-C6 dialkylamino, SH;~S03H;
S03(C~-C6 alkyl), 50=(C~-C6 alkyl), SO(C~-C6 alkyl), and X represents oxygen; sulfur; CH=CH or NR,o wherein R9 is H, C~-C6 alkyl, Cl-Cb alkenyl, C.r-C~6 arylalkyl wherein the aryl is C6-Coo aryl and the alkyl is C~-alkyl, C~-C~6 arylalkenyl wherein the aryl is C6-C,p aryl and the alkenyl is alkenyl; Cz-C6 allcanoyl, with the proviso that when RZ is hydroxy Rs cannot be hydrogen, e~ecept when is hydrogen, OCl-izOCH3, OCHZOCzHs or OC(Ph)s;
and pharmacologically acceptable salts thereof.
By aryl the following definitions are intended throughout the whole~atent application.
Aryl may be unsubstituted or mono-, di- or trisubstituted indep~er~dently with ?5 hydroxy, halo, vitro, cyano, thiocyanato, trifluoromethyl, Cs-C3 alkyl, Cl-WO 95131463 ~~ ~ A PCTlSE95/00503 c ?: ~, , alkoxy, COzH, C02 (CT-C3)alkyl, CONH2, CONH(Ct-C., allcyl), CON(C~-C3 alkyl)z, CO(Cl-C3 allcyl), amino, (C~-C3 monoalkyl)amino, (CI-C3 dialkyl)amino, CS-Cs cycloalkylamino, (C~-C3 alkanoyl)amino, SH, S03H, S03 (Cl-C~ alkyl), SOZ (C~-alkyl), SO(C~-C3 alkyl), C~-C3 alkylthio or Cl-C3 alkanoy~lthio.
In a preferred embodiment Rt is selected from allyl, cinnamyl, cyclopropylmethyl or cyclobutylmethyl;
RZ is selected from methoxy, ethoxy, n-propyloxy, benzyloxy, benzyloxy substituted in the aromatic ring with F, Cl, NO2, CN, CF3, CH3 or OCH3;
allyloxy, cinnamyloxy or 3-phenylpropyloxy;
R3 is selected from hydrogen, methyl, ethyl, benzyl or allyl;
R4 is selected from hydroxy, methoxy, methoxymethoxy or acetyloxy;
RS and Rs are each and independently selected from hydrogen, vitro, cyano, chloro, fluoro, bromo, trifluoromethyl; COZH; COZ CH3, CONH2; CONH CH3, CH3, SH; SOzNH2; N(CH3)Z, SOZ CH3; and X is selected from O, NH, N CH3, N-benzyl, N-allyl.
In an especially preferred embodiment Rl is allyl or cydopropylmethyl;
RZ is selected from methoxy, ethoxy, n-propyloxy, benzyloxy substituted in the aromatic ring with chlorine;
R3 is selected from hydrogen or CH3;
R4 is hydroxy WO 95/31463 ~ ~ PCT/SE95/00503 RS and R6 are each independently selected from hydrogen, COZH, CONH2, SOZNH2 or SO2CH3; and _-X is selected from O or NH.
The best mode known at present is to use the compounds of Examples 1, 6, 8,18, 24, 41 and 42.
The novel compounds'accord'ing to the invention are useful as immunsuppressive agents and/or as analgesics, and also after CNS-injuries by exerting a brain-cell protecting effect.
Earlier studies (cf. page 3) accomplished with S-selective opioid antagonists have shown that this class of compounds exhibits immunosuppressive effects. Thus, the compounds of formula (I) of the present invention may be used for suppressing the rejection of transplants after organ transplantations and may be used in the treatment of rheumatic diseases, e.g. rheumatoid arthritis and/or as analgesics.
Pharmaceutically and pharmacologically acceptable salts of the compounds of formula I are also comprised in the invention. Suitable salts are inorganic salts such as HCl salt, HBr salt, sulfuric acid salt, phosphoric acid salt. Organic acid salts such as methanesulfonic acid salt, salicylic acid salt, fumaric and salt, malefic add salt, succiruc acid salt, aspartic acid salt, citric acid salt, oxalic acid salt, orotic add salt, although the salts are not restricted thereto, can also be used according to the invention.

Preparation The compounds represented by formula (I) may be. obtained by the following methods:
Thebaine of the formula is being treated with dialkylsulfates, fluorosulfonic acid alkyl esters, alkylsulfonic acid alkyl esters, arylsulfonic acid alkylesters, alkyl halides, aralkyl halides, alkylsulfonic acid aralkyl esters, arylsulfonic acid aralkyl, arylalkenyl halides, chloroformates, in solvents such as tetrahydrofurane or diethyl ether using a strong base such as n-butyl lithium, lithium diethyl amide or lithium diisopropyl amide at low temperatures (-20 to -80 °C) (s. Boden et al., J.org.Chem.,Vo1.47:
1347-1349,1982; Schlnidhammer et al., Helv.Chim.Acta, Vo1.71:642-647,1988), giving compounds of the formula II
C H3C ~C H3 wherein R is CI-C6 alkyl; CI-C6 alkenyl; C~-C~6 aralkyl wherein the aryl is C6-Clo aryl and the alkyl is Cl-C6 alkyl; C~-C~6 arylallcenyl wherein the aryl is C6-CIO aryl and the WO 95/31463 PCTlSE95100503 alkenyl is Ct-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C~-C6 alkoxy and the alkyl is C~-C6 alkyl; COZ (Cl-C6 alkyl); The substituted thebaine derivatives ' . (formula (II)) or thebaine are converted into the corresponding 14-hydroxycodeinones according to formula III
C
wherein R is as defined above or being hydrogen, by reaction with performic acid (s. Schmidhammer et al., Helv.Chim.Acta, Vol.
71:1801-1804,1988) or m-chloroperbenzoic acid at a temperature between 0 and 60 °C The preferred procedure is the reaction with performic acid at 0-10 °C (H.
Schmidhammer et al., Helv.Chim.Acta, Vol. 71:1801-1804, I988). These 14-hydroxycodeinones being treated with dialkyl sulfates, alkyl halides, alkenyl halides, aralkyl halides, arylalkenyl halides, chloroformates, in solvents such as N,N-dimethyl formamide or tefrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide giving compounds of formula (IV), (N) wherein .10 R~ is Cl-C6 alkyl, C2-C6 alkenyl; C~-C~6 arylallcyl wherein the aryl is C6-Coo aryl and the alkyl is C~-C6 alkyl, C.r-C~6 arylalkenyl wherein the aryl is Ce-Coo aryl and the alkenyl is c2-c6 alkenyl, C~-Cb alkanoyl, C~rCro arylalkanoyl wherein the aryl is C6-C~4 aryl and the alkyl is C,-C6 alkyl, C?-Coo arylalkenoyl wherein the aryl is ~ C6-C~4 aryl and the alkenoyl is C2-C6 alkenoyl;
R~ is hydrogen; C~-C6 alkyl; C2-C6 allcenyl C.r-C~6 arylalkyl wherein the aryl is C6 Coo aryl and the alkyl is Cl-C6 alkyl; C~-C~6 arylalkenyl wherein the aryl is C6-Coo aryl and the alkenyl is CZ-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C~-C6 alkoxy and the alkyl is C~-C6 alkyl; CO=tC~-C6 alkyl);
which in turn are reduced by catalytic hydrogenation using a ~catlayst such as palladium on charcoal and solvents such as methanol, ethanol or..glacial acetic acid to give compounds of formula (~

wherein R, is C~-C6 alkyl, C.~-rC~b arylalkyl wherein the aryl is C6-Coo aryl and the alkyl is C~~6 alkyl, C1-C6 alkanoyl, C~-C~6 arylalkanoyl wherein the aryl is C6-Coo aryl and the alkanoyl is C~-C6 alkanoyl; and Rz is hydrogen; C~-C6 alkyl, C2-C6 alkenyl C~rC~b arylalkyl wherein the aryl aryl and the alkyl is C~-C6 alkyl; C~-C~6 arylalk~enYl wherein the aryl is C6-Coo aryl and alkenyl is Cz-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C1-C6 alkyl;
COZ(C~-C6 alkyl);
Thereafter N-demethylation can be carried out using chloroformates or cyanogen bromide to give intermediates of formula (VI) Na C H30 ~O~ R2 ~O
wherein Rl and Ri are as defined above in formula (IV); and R3 is CO=CHC1CH3, COzCH=C'H~, C02CHzCCI3, COzCI-izCH~, CO=1'h, CSI or the like.
The intermediate carbamates of formula (VI) can be cleaved by refluxing in alcohols tin the case of 1-chloroethyl carbamates), by addition of hydrogen halides or halogen and subsequent refluxing in akohols (in the case of vinyl carbamates), or by reductive cleavage using zinc in glacial acetic acid or methanol tin the case of 2,2,2-trichloroethyl carbamates). Other carbonates may be cleaved using aqueous acid, alkali or hydrazine. 3'he interanediate cyanannides of formula (VI) can be cleaved by acid hydrolysis. Alkylation of the corresponding N-nor derivatives of formula (V>I) N~

wherein R~ and Ri are as defined above in-formula (V), can be accomplished with alkenyl halides, cycloalkylalkyl halides, cycloalkenylalkyl halides, aralkyl halides, arylalkenyl halides, in solvents such as dichloromethane, chloroform; or N,1~-dimethyl formamide in the presence of a base such as sodium hydrogen carbonate or potassium carbonate to yield derivatives of formula (VIII) Nib C
wherein Ri and Rx are as defined above in formula (V); and R3 represents C2-C6 alkenyl; C7-C~6 arylalkyl wherein the aryl is C6-Clo aryl and the alkyl is C~-C6 allryl; C?-C~6 arylalkenyl wherein the aryl is C6-Coo aryl and the alkenyl is C2-C6 alkenyl; C;-Cso cycloalkylalkyl wherein the cydoallcyl is C3-rydoalkyl and the alkyl is C~-C4 alkyl; C~-Coo cycloalkylalkenyl wherein the cydoalkenyl is C3-C6 cycloalkenyl and the alkyl is C~-C4 alkyl;

Ether cleavage can be carried out using boron tribromide (in a solvent such as dichloromethane or chloroform at about 0 °C), 48 % hydrobromic acid ~r~flux), or other well known reagents for ether cleavage. The resulting phenols of formula (IX) ~~) wherein R~, Rz and R3 are as defined above, are being alkylated using alkyl halides, alkyl sulfates, sulfonic acid.esters, aralkyl halides, arylalkenyl halides or acylated using carbonic acid chlorides, or~carbonic add esters to yield compounds of formula (7~
~) wherein R~, R2 and R3 are as deFuted above; and R4 is hydrogen, C~-C6 alkyl, C~-Cl6 arylalkyl wherein the aryl is C6rCyo aryl and the alkyl is C~-C6 alkyl, C:-C6 alkenyl, Cr-Cib arylalkenyl wherein the aryl is C6-Coo aryl and the alkenyl is Cz.-C~ alkenyl; Cl-C6 alkanflyl, C~~Ci6 arylalkanoyl wherein the aryl is C6-Coo aryl and the aikanoyl is C~-C6 alkanoyl, Cz-Coo aikyloxyalkyl wherein allcyloxy is C~-C~ alkylouy and alkyl is C~-C6 alkyl, W0951314G3 ~~~ I PCTlSE95100503 14 , i ;1;
Compounds of the formula (I) wherein R2 is hydroxy may be obtained from compounds of formula (III) wherein R is defined as above. These compounds may be reduced by catalytic hydrogenation using a catalyst such as palladium on charcoal and solvents such as methanol, ethanol, or glacial acetic acid to give compounds of the formula (V) wherein Rl is hydrogen and RZ is defined for R in formula (II).
The following reaction sequence and procedures leading to compounds of formulas (VI), (VII), (VIII), (IX) and (X) wherein the substituent in position 14 is hydroxy and the other substitutents are defined as above, is analogous to the reaction sequence and procedures described above. Further conversion to compounds of the formula (I) wherein RZ is hydroxy is described below.
Compounds of the formula (I) wherein R2 is hydrogen may be obtained from compounds of the formula (II) wherein R is as defined above or hydrogen.
Catalytic hydrogenation followed by acid hydrolysis (s. Boden et al., J. Org.
Chem. Vol. 47.1347-1349, 1982) may provide compounds of formula (XI) (X~
(XIa): R=H (dihydrocodeinone) wherein R is as def"med above in formula (II) or hydrogen.
Compounds of the formula (XI) and (XIa) (Mannich and Lowenheim, Arch.Pharm.Vol. 258:295,1920) can be converted into compounds of formulas (V), (VI), (ViI), (VIII), (IX), and (X) wherein the substituent in position 14 is hydrogen WO 95/31463 - ~ , ~ PCTISE95I00503 and RZ and R3 are as defined above, similarly as outlined above. Further conversion into compounds of the formula (I) wherein Rz is hydrogen is described below.
5 Compounds of the formula (I) wherein R4 is hydrogen may be prepared from compounds of the formula (IX) by alkylation with 5-chloro-1-phenyl-1H-tetrazole to give the corresponding phenyltetrazolyl ethers of the formula XII) (Xlfj T
10 wherein R~, Itz and R3 are as defined above and R~ also can be CH3, and T
is phenyltetrazolyl.
Catalytic hydrogenation may afford (H. Schmidhammer et al., J. Med. Chem. Vol.
27:1575-1579,1984) compounds of the formula (XIII) (XII~
wherein Rl, RZ and R3 are as defined above and Rl also can be CHy In the case R~ is CH3, the N-methyl group hasao lie'xemoved and the nitrogen alkylated as described above.
Alternatively, compounds of formula (I) wherein RI represents allyl or cyclopropylmethyl and R3 represents H can be obtained by a shorter route starting either from naloxone (XIVa) or naltrexone (XIVa).
(XN) (XIVa): Naloxone - R is allyl (XIVb): Naltrexone - R is cyclopropylmethyl.
The 3-hydroxy group of crompounds of formula (XIV) is being protected by alkylation with benzyl bromide, methoxymethyl bromide, ethoxymethyl bromide or trityl chloride (triphenyhnethyl chloride) in a solvent such as N,N-dimethyl formamide or dichloromethane in the presence of a base to yield compounds of formula (XV) (XV) wherein R is allyl or cyclopropylmethyl and Y = CHZPh, CH20CH3, CHZOCZHS or C(Ph)3.

These compounds are alkylated, alkenylated, cydoaUcylalkylated, arylalkylated or arylalkenylated with dialkyl sulfates, alkyl halides, alkenyl halides, arylalkyl halides or arylalkenyl halides in solvents such as ht,h1-dimethyl formamide or tetrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide. The resulting 6-0,14-0-dialkylated compounds of formula (XVI) own C H ORZ
wherein R.~ is allyl or cyclopropylmethyl; and Rz is C~-C6 alkyl, C2-C6 alkenyl, C.r-C16 arylalkyl wherein the aryl is C6-Coo aryl and the alkyl is C,-C6 alkoxy, C~-C~6 arylalkenyl wherein the aryl is C6-C,o aryl and alkenyl is CZ-C6 alkenyl; and Y as defined above;
can be hydrolized with diluted acids like hydrochloric acid or sulfuric aad to afford compounds or formula (7CVII) R.
wherein R~ is aDyl or cyclopropylmehtyl; and r ~: 7j W095131463 1$ ~ PCTISE95/O(1503 RZ is as defined above (formula XVI).
In the case RZ is alkenyl or arylalkenyl the double bond may be reduced by catalytic hydrogenation to afford the corresponding saturated derivatives.
Further conversion into compounds of formula (I) is described below.
Alternatively, compounds of formula (I) wherein Rt represents allyl or cyclopropylmethyl and R3 represents H can be prepared also via the following route: The carbonyl group in position 6 of naloxone (XVa) and naltrexone (XVb), respectively, is being protected by reaction with ethylene glycol in the presence of an acid (e.g. methanesulforuc acid) at temperatures between 20 and 200 °C to give ketals of formula (XVIII) (XV II~
wherein R is allyl or cyclopropylinethyl.
The 3-hydroxy group of these ketals is being protected by aIkylation with benzyl bromide, methoxymethyl bromide, ethoxymethyl bromide or trityl chloride in a solvent such as N,N-dimethyl formamide or dichloromethane in the presence of a base to yield compounds of formula (XIX) r WO 95131463 ~ PCT1SE95100503 19 ~~~ r~~'k~
YO
wherein R is allyl or cyclopropylmethyl and Y is as defined above.
These compounds are alkylated, alkenylated, arylalkylated or arylalkenylated with dialkyl suflates, alkyl halides, alkenyl halides, arylalkyl halides or arylalkenyl halides in solvents such as N,N-dimethyl formamide or tetrahydrofurane using a strong base such as sodium hydride, potassium hydride or sodium amide. The resulting compounds of formula (XX) wherein Its is allyl or cyclopropylmethyl, Rz is as defined above (formula (XVI)) and Y is as defined above can be hydrolized in diluted acids like hydrochloride and or sulfuric acid (a typical mixture for hydrolysis is: concentrated HCI: MeOH: HZO 3/6/1 v/v/v) to afford compounds of formula (XVII). Compounds of formula (I) wherein RI

WO95131463 ~ ~ ' . . PCTISE95100503 represents allyl or cyclopropyl-ethyl, R3 represents H, and X represents NH or O
can be prepared from compounds of formula (XV1I) as described below.
Compounds of the formula (I) wherein R3 is as defined above and X represents S NH are obtained by reaction of compounds of formula (VIII), (X) or (XIII) with phenylhydrazine or substituted phenylhydrazine in solvents such as methanol, ethanol or glacial acetic acid in the presence of methanesulfonic acid, HCI or HBr.
Phenylhydrazine substituted at the aromatic ring with hydroxy, halogen, C~-C6 alkyl, Ci C6 alkoxy, amino, vitro, cyano, thiocyanato, trifluoromethyl, C02H, 10 (C~-C6) alkyl, CONHZ, CONH CCl-C6 allcyl), CON (C~-C6 alkyl)z, SOzNHz, SOZ
(Ct-C6) alkyl or the like may be employed. The reaction may be carried out at a temperature between 20 and 160 °C, preferably between 20 and 80 °C.
Compounds of formula (I) wherein R3 is as defined above and X represents O are 15 obtained by reaction of compounds of formula (VIII), (IX), (X) or (XIII) with O-phenylhydroxyl amine or substituted (at the aromatic ring) O-phenylhydroxyl-amine in solvents such as methanol ethanol, or glacial acetic acid in the presence of methanesulfonic acid, HCl or HBr. O-phenylhydroxylamine substituted at the aromatic ring with hydroxy, halogen, CI-C~ alkyl, CI-C6 alkoxy, amino, vitro, 20 cyano, thiocyanato, trifluoromethyl, C02H, COZ (Cl-C6) alkyl, CONH2, CONH
(Cl-C6 alkyl), CON (Cl-Cb alkyl)2, SOzNHz, SOZ (CI-C6) alkyl or the like may be employed.
The invention will now be described in more detail by the following examples which are not to be construed as limiting the invention.

~ W095/31463 ; PCTISE95100503 , Examples Example 1 Synthesis of 17-(CydopropylmethyD-6,7-dehydro-4,5a-epoxy-14-ethoxy-3-hydroxy-5-methyl-6,7-2',3'-indolomorphinan hydrochloride (compound 1).
A mixture of 14-O-ethyl-5 ~methylnaltrexone (H. Schmidhammer et al, Helv.
Chim. Acta, Vol. 76: 476-480,1993) (580 mg,1.51 mmol), phenylhydrazine hydrochloride (394 mg, 2.72 mmol), and 7 ml of glacial acetic acid was refluxed for 23 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH4OH and extracted with CHZCIz (3x30 ml). The combined organic layers were washed with H20 (3x80 ml), dried over NazS04 and evaporated. The remaining residue (615 mg brownish foam) was dissolved in little MeOH and EtaO/HCl was added. Thus, 550 mg (95%) of the compound 1 were isolated. For analysis a small amount was recrystallized from MeOH. m.p. > 260°C
(dec.) IR
(KBr): 3200 ('NH, NH, OH)cni 1. CI-MS:m/z 457 (M- +1).'H-NMR ((db)DMSO): b 11.34, 9.21. and 8.55 (3 s, 'NH, NH, OH), 7.32 (m, 2 atom. H), 7.08 (t, J =
8.1 Hz, I
atom. H), 6.94 (t, J = 8.1 Hz, I atom. H), 6.62 (d, J = 8.1 Hz,1 atom. H);
6.55 (d. J =
8.1 Hz, 1 atom. H),1.86 (s, CH3 C(5)),1.OI (t, J = 6.8 Hz, 3H, CH3CHz0).
Analysis calculated for C29 H~Nz03.HC1.H20 (511.06): C 68.16, H 6.90, N 5.48, Cl 6.94;
found: C 67.87, H 6.88, N 5.30, Cl 7.28.

~1~9140 zz a:
Exam_p1e 2 Synthesis of 17-Allyl-6,7-dihydro-4,5a-epoxy-14-ethoxy-3-hydroxy-5-methyl-6,7-2',3'-indolomorphinan hydrochloride (compound 2).
A mixture of 14-O-ethyl-5-methylnaloxone (H. Schmidhammer et al., Helv. Chim.
Acta Vol. 76:476-480,1993) (1.2g, 2.66 mmol), phenylhydrazine hydrochloride (577 mg, 3.99 mmol), and 15 ml of glacial acetic acid was refluxed for 24 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH40H
and extracted with CHZCIz (3x80 ml),1x30 ml). The combined organic layers were washed with H20 (3x80 ml, 1x30 ml), dried over Na2504 and evaporated. The residue (1.3 g yellow-brown foam) was purified with column chromatography (alumina basic grade IV, elution with CHZCIz). The corresponding fractions were combined and evaporated to give a colorless oil which was converted into the hydrochloride salt in the usual way and crystallized from MeOH/diethyl ether to yield 200 mg (179°) of the title compound 2. M.p. 168-170°C. IR
(KBr):3200('NH,OH)cffi'. CI-MS: M/z 443 (M'+1).'H-NMR (CD30D):
8 7.39 (dd, J=7.8, 7.8 HZ, 2 arom. H), 7.14 (t, j=7.8 hz, i arom.H), 7.01 (t=7.8 HZ,1 arom. H), 6.67 (s,2 arom. H), 6.02 (m, l olef. H), 5.72 (m, 2 olef. H), 1.99 (s, CH3-C(5)), 1.09 (t, J=6.8 Hz, CH3). Analysis calculated for C~H3o1VZO3.
HCI. 1.5 HZO (506.05):-C 66.46, H 6.77 N 5.54, Cl 7.01; found: C 66.55, 6.68, N 5.39, Cl 6.98.

b t\
WO 95131463 ~ PCTlSE95100503 Eaxmple 3 Synthesis of 6,7-Dehydro-4,5a-epoxy-14-ethoxy-3-hydroxy-5-methyl-17-(2-phenyl)ethyl-6,7-2',3'-indolomorphinan hydrochloride (compound 5).
A mixture of 4,5a-epoxy-14-ethoxy-3-methoxy-5-methylmorphinan-6-one hydrochloride (H. Schmidhammer et al., Helv. Chim. Acta Vol. 76, 476-480,1993) (3.0 g, 7.88 mmol), potassium carbonate (3.9 g, 28.2 mmol), 2-phenylethyl bromide (1.41 ml, 10.4 mmol), and of 20 ml anhydrous N,N-dimethyl formamide was stirred at 80°C (bath temperature) for 2h. After cooling and addition of 130 ml of HZO, the mixture was extracted with diethyl ether (3x60 ml). The combined organic layers were washed with H20 (3x70 ml), dried over Na2S04 and evaporated. The residue (3.6 yellow oil) was crystallized from MeOH to afford 2.1 g (70%) of 4,5a-epoxy-14-ethoxy-3-methoxy-5-methyl-17-(2-phenyl)ethylmorphinan-6-one (compound 3). M.p. 86-89°C. IR (KBr):1725 (CO) cm'. CI-MS: m/z 448 (M~+1).'H-NMR (CDC13): 8 7.21 (m, 5 arom. H), 6.64 (d,J=8.2 Hz, 1 arom. H, 6.54 (d, J=8.2 Hz, 1 arom. H.), 3.85 (s, OCH3),1.60 (s, CH3-C(5)),1.12 (t, J=6.8 Hz, CH3). Analysis calculated for C~H~1V04 (447.55): C
75.14, H 7.43, N 3.13; found: C 75.04, H 7.69, N 3.26.
A solution of the compound 3 (1.5 g, 3.35 mmol) in 5 ml of 48% HBr was refluxed for 30 min and then evaporated. The residue was dissolved in MeOH and again evaporated (this procedure was repeated twice) to give a grey crystalline residue (1.7 g) which was treated with hot MeOH to yield 950 mg (63%) of the compound 4. M.p.>270°C. IR (KBr): 1720 (CO) cm'. CI-MS: m/z 434 (M'+1). 1H-NMR
(DMSO-db): 8 9.38 and 8.48 (2 s, 'NH, OH), 7.33 (m,5 arom. H), 6.68 (d, J=8.2 Hz, i arom. H), 6.64 (d, J=8.2 Hz, l arom. H),1.51 (s, CFi3-C(5)),1.34 (t, J=6.8 Hz, CH3).

R'095/31463 ~~~ PCrlSE95100503 Y
Analysis calculated for C~H3~NO4. HBr (514.45):C 63.04, H 6.27, N 2.72, Br 15.53;
found: C 63.15, H 6_48, N 2.61, Br 15.37 A mixture of the compound 4 (700 mg, 1.61 mmol), phenylhydrazine hydrochloride (513 mg), 3.54 mmol), and 15 ml of glacial acetic acid was refluxed for 6 h. The reaction mixture was poured on ice, alkalized with cone. NH40H
and extracted with CH2CIa (3x80 ml, 1x30 ml). The combined organic layers were washed with H20 (3x80 ml), dried over Na2S04 and evaporated. The residue (600 mg slightly brown foam) was converted into the hydrochloride salt in the usual IO way and crystallized from MeOH/diethyl ether to yield 360 mg (51 %) of the title compound 5 as slightly pink crystals. M.p.>225°C. IR (KBr):3400 and 3200 ('NH, NH,OH). CI-MS:m/z 507 (M'+1).'H-NMR (DMSO-db):811.34, 9.19 and 8.97 ('NH, NH, OH), 7.34 (m, 7 arom. H), 7.08 (t, J=7.9 Hz, 1 arum.), 6.94 (t, J=7,9 Hz, l arum.
H), 6.62 (d, J=8.4 Hz, 1 arom. H), 6.57 (d, J=8.4 Hz, l arom. H), 1.87 (s, CH3-15 C(5)),0.96 (t, J=6.9 Hz, CH3). Analysis calculated for C~H~N203. HC1.2 Hz0 (579.14): C 68.44, H 6.79, N 4.84, Cl 6.12; found: C 68.81, H 6.55, N 4.72, Cl 6.40.
xam 1 4 20 Synthesis of 17-Allyl-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-methoxy-5-methyl-6,7-2',3'-indolomorphinan hydrochloride (compound 6).
A mixture of 14-O-methyl-5-methylnaloxone (H. Schmidhammer et al., Helv.
Chim. Acta Vol. 77:1585-1589,1994) (1.0 g, 2.8 mmol), phenylhydrazine 25 hydrochloride (728 mg, 5.04 mmol), and 15 ml of glacial acetic acid was refluxed for 24 h. After cooling, the reaction mixture was poured on ice, alkalized with cone. NH40H and extracted with CIizCiz (3x80 ml,1x30 mI). The combined organic layers were washed with Hz0 (3x80 ml), dried over NazSO,~ and WO 95!31463 ~ ~ PCTISE95/00503 evaporated. The residue (1.1 g brownish foam) was converted in the usual way into the hydrochloride salt and crystallized from acetone to yield 190 mg (19%) of the tide compound 6 as slightly brown crystals. M.p. >Z80°C. IR (KBr):
3200 ('NH, NH,OH),'H-NMR: 8 7.32 (dd, J=7.9, 7.9 Hz, 2 arom. H), 7.06 (t, J=7.9 Hz, 1 arom.
H), 6.93 (t, =7.9 Hz, I arom. H), 6,63 (d, J=8.2 Hz, 1 arom. H), 6.55 (d, J=8.2 Hz, I
arom. H), 6.02 (m, lolef.H), 5.63 (m, l olef. H), 3.15 (s, OCH3), 2.07 (s, CH3-C(5)).
Analysis calculated for CnH~NZ03. HCI. 1.7 H20. 0.9 MeOH (524.44): C64.41, H
7.09, N 5.22; found: C 64.44, H 6.87, N 4.94.
m 1 5 Synthesis of 6,7-Dehydro-4,5a-epoxy-3-hydroxy-14-methoxy-5-methyl-17-(2-phenyl)ethyl-6,7-2',3'-indolomorphinan Hydrochloride (compound 9).
I5 A mixture of 4,5a-epoxy-3,14-dimethoxy-5-methylmorphinan-6-one hydrochloride (H. Schmidhammer et al., Helv. Chim. Acta Vol. 77:1585-1589, 1994) (2.24 g, 6.I2 mmol), potassium carbonate (3.0 g, 2L9 mmol), 2-phenylethyl bromide (1.05 ml, 7.74 mmol), and 15 ml of anhydrous N,N-dimethyl formamide was stirred at 80°C (bath temperature) for 2 h. After cooling and addition of 110 ml of HiO, the mixture was extracted with diethyl ether (3x60 ml). The combined organic layers were washed with Hz0 (3x70 ml), dried over Na2S04 and evaporated. The residue (2.9 yellow oil) was converted into the hydrobromide salt in the usual way and crystallized from MeOH to give 1.4 g (63%) of 4,5a-epoxy-3,14-dimeEhoxy-5-methyl-17-(2-phenyl)ethylmorphinan-6-one hydrobromide (compound 7) as colorless crystals. A small portion of this material was recrystallized from MeOH for analyses. M.p. 94-96°C. IR (KBr): 3400 ('NH),1720 (CO) cni'. CI-MS: m/z 434 (M'+1).'H-NMR (DMSO-ds) & 10.15 (s, 'NH), 7.30 (m, 5 arom. H), 6.74 (d, J=8.2 Hz, 1 arom. H), 6.68 (d, J=8.2 Hz, I arom.), 3.87 (s, WO 95/31463 ~ ~ r ;~ ' ~ ~ , PCTISE95I00503 OCH3 C(3)), 3.58 (s, OCH3 C(14)),1.60 (s, CH3 C(5)). Analysis calculated for Ca~H3~N04. HBr (514.44): C 63.04, H 6.27, N 2.72; found: C 63.18, H 6.60, N
2.39.
A solution of the compound 7 (1.4 g, 3.32 mmol) in 5 ml of 48% HBr was refluxed for 30 min and then evaporated. The residue was dissolved in MeOH and again evaporated (this operation was repeated once) to afford a brownish crystalline residue (1.8 g) which was treated with hot MeOH to yield 590 mg (42%) of the compound 8.HBr. A small portion was recrystallized for analyses.
M.p.>316°C. IR
(KBr):3400 ('NH, OH),1722 (CO)cni 1. CI-MS: m/z 420 (M'+1). 1H-NMR (DMSO-db) b 8.95 and 8.45 (2s, 'NH,OH), 6.90 (m, 5 arom. H), 6.23 (dd, ]=8.2, 8.2 Hz, 2 arom. H), 2.97 s, OCH3), 1.08 (s, CH3 C(5)). Analysis calculated for C26HZ9NO4.
HBr. 0.2 MeoH (506.85)_ C 62.D9, H 6.13, N 2.76, Br 16.77; found: C 61.79, H
6.18, N
2.63, Br 16.12. -A mixture of the compound 8. HBr (468 mg, 0.93 mmoI), phenylhyrazine hydrochloride (343 mg, 2.36 mmoI), and 15 ml of glacial acetic was refluxed for 7 h. After cooling, the reaction mixture was poured on ice, alkalized with con.
NH40H and extracted with CH2CIz (3x70 m1,1x30 ml). The combined organic layers were washed with Ha0 (3x80 ml), dried over Na2S04 and evaporated. The residue (410 mg slightly brown foam) was converted into the hydrochloride salt in the usual way and crystallized from MeOH/diethyl ether to give 390 mg (83%) of the title compound 9 as slightly pink crystals. An analytic sample was obtained by recrystallization of a small portion of this material from MeOH/diethyl ether.
M.p. 257-260°C (dec.). IR (KBr): 3460 ('NH, NH, OH) cni'. CI-MS:
m/z 493 (M-+1).'H-NMR (DMSO-db) & 11.30, 9.20 and 9.05 (3 S, -1V'H, NH, OH), 7.25 Cm, arom. H), 7.10 (t, J=8.2 Hz, l arom. H), 6.96 (t, J=8.2 Hz, l arom: H), 6.59 (dd, J=
8.2, 8.2 Hz, 2 arom. H)~ 3.32 (s, OCH3),1.87 (s, CH3-C(5)). Analysis calculated for WO 95131463 PCTlSE95100503 GszHazNzOa- HC1. 3.7 MeOH (647.63): C 66.21, H 7.44, N 4.33; found: C 66.04, H
7.13, N 4.60.
Exam 1 Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14 methoxy-5-methyl-6,7-2',3'indolomorphinan Hydrochloride (compound 10).
t A mixture of i4-0-methyl-5-methylnaltrexone (H.Schmidhammer et al., Helv.
Chim. Acta Vol. 77:1585-1589,1994) (620 mg, i.68 mmol), phenylhydrazine hydrochloride (365 mg, 2.52 mmol), and 7 ml of glatial acetic acid was refluxed for 17S h. After cooling, the reaction mixture was poured on ice, alkalized with NH40H and extracted with CHZCIz (3x70 ml, 1x20 ml). The combined organic layers were washed with Hz0 (3x80 ml), dried over NaZSOø and evaporated. The residue (1.11 g brown foam) was purified by column chromatography (silica gel 230-400 mesh, mobile phase CHZCIz/MeOH 90:9). The corresponding fractions were combined and evaporated to afford a slightly yellow foam which was dissolved in MeOH and treated with ethereal HCl to yield 520 mg (65%) of the compound 1D as colorless crystals. For analyses a small sample was recrystallized from MeOH: M.p. >250°C (dec.). IR (KBr):3515 and 3220 ('NH, NH, OH)cni I. CI-MS: m/z 443 (M-+1).1H-NMR (DMSO-db): b 11.30, 9.12, 8.93 (3 s,'NH, NH, OH), 7.34 (m, 2 arom. H), 7.09 (t, J=8.3 Hz, 1 arom. H), 6.95 (t, J=8.3 HZ, I arom.
H), 6.63 (d, J=8.1 Hz, l arom. H), 6.56 (d, J=8.1 Hz, l arom. H), 3.24 (s, OCH3),1.87 (s, Cfi3-C(5)). Analysis calculated for C~Fi3oN203. HCI. 0.7 H20 (491.67):C 68.41, H
6.64, N
5.70, CI 7.21; found: C 68.52, H 6.86, N 5.65, Cl 7.48.

. r ~.'_ ,, PCTISE95100503 ~~,~t ~ 2s Example 7 Synthesis of 17-Allyl-6,7-dehydro-4,5a-epoxy-3-hydroxy-5-methyl-14-n-propyloxy-6,7-2',3'-indolomorphinan. CH3S03H (compound 15).
A mixture of 7,8-dihydro-5-methyl-14-n-propyloxycodeinone described in our copending application with priority from May 18,1994) (9; 2.67 g, 7.19 mmol), KHC03 (3.6 g, 35.93 mmol), 1-chloroethyl chloroformate (4.73 ml, 43.12 mmol), and 35 ml of 1,2-dichloroethane was stirred under reflex for 3.5 h. After cooling, the inorganic material was filtered off and the filtrate evaporated. The residue (4.67 g of a yellowish oil of 17-(1-chloroethoxy)- carbonyl-4,5a-epoxy-3-methoxy-5-methyl-14-n-propyloxvmorphinan-6-one (compound 11); pure by TLC) was not further purified and characterized. A solution of the compound 11 in MeOH was refluxed for 1 h and then evaporated. The residue (3.54 g slightly brown foam) i5 was crystallized from 2.5 ml MeOH/2 ml diethyl ether to give 1.68 g (66%) of 4,5a-epoxy-3-methoxy-5-methyl-14-n-propyloxy-morphinan-6-one hydrochloride (compound 12). M.p. 186-188°C. IR (KBr): 3425 ('NH2),1725 (CO)cui'. EI-MS: mlz 357 (M'). 'H-NMR (DMSO-db): a 10.11 and 8.15 (2 broad s, 'NHZ), 6.83 (d, J=8.2 Hz, 1 arom. H), 6.74 (d, J=8.2 Hz, 1 arom. H), 3.78 (s, CH30),1.48 (s, CH3-C(5)), 0.95 (t, J=7.4 Hz, CH3). Analysis calculated for CZIHZTN04. HCI. 0.6 MeOH
(413.14): C 62.80, H 7.42, N 3.39, Cl 8.58; found: C 62.66; H 7.34, N 3.40, Cl 8.98. A
mixture of the compound 12 (1.45 g, 3.68 mmol), allyl bromide (0.36 ml, 4.06 mmol), potassium carbonate (2.9 g, 20.8 mmol), and 10 ml of anhydrous N,N-dimethyl formamide was stirred at 80°C (bath temperature) foi 1.5 h.
The inorganic solid was filtered off and the filtrate evaporated to give 1.7 g of a yellowish oily residue. This residue was partitioned between CHZCiz and H20.
The organic layer was washed with HZO and brine, dried over Na2S0~ and evaporated. The residue (1.375 g of a slightly yellow oil) was crystallized from ethanol to yield 1.28 g (88%) of 17-allyl-4,5a-epoxy-3-methoxy-5-methyl-14-n-propyloxymorphinan-6-one (compound 13) as slightly yellow crystals. M.p. 122-124°C. IR(KBr): 1720 (CO)cm t. EI-MS: m/z 397 (M').'H-NMR (CDC13): 8 6.63 (d, J=8.3 Hz, 1 arom. H), 6.55 (d, J=8.3 Hz, 1 arom. H), 5.79 (m, l olef. H), 5.13 (m, 2 olef.I~y, 3.84 (s, OCH3),1.60 (s, CH3-C(5)), 1.00 (t, J=7.4 Hz, CH3). Analysis calculated for Cz4H3~NO4 (397.51): C 72.52, H 7.86, N 3.52; found: C 72.14, H
7.76, N 3.44. A 1 M solution of boron tribromide in CHZCIz (10.8 ml) was added to an ice-cooled solution of the compound 13 (577 mg, 1.45 mmol) in 75 ml of CHZCiz at once. After stirring at 0-5°C for 2 h, a mixture of 20 g ice and 4 ml of cone. NH40H
was added. The resulting mixture was stirred at room temperature for 30 min and the extracted with CHZCIz (3x50 ml). The combined organic layers were washed with brine (70 ml), dried over NaZSO~ and evaporated. The residue (600 mg brownish foam) was converted into the hydrobromide salt in the usual way and crystallized from MeOH to afford 314 mg (47%) of 17-allyl-4,5a-epoxy-3-hydroxy-5-methyl-14-n-propyloxymorphinan-6-one hydrobromide (compound 14). M.p.
244-247°C (dec.). IR (KBr): 3441 and 3332 ('NH, OH), 6.68 (d, J=8.2 Hz, l arom. H), 6.62 (d, J=8.2 Hz, 1 arom. H), 5.92 (m, 1 olef. H), 5.67 (m,2 olef. H),1.49 (s, CH3-C(5)), 0.96 (t, J=7.2 Hz, CH3).
A mixture of the compound 14 (300 mg, 0.65 mmol), phenylhydrazine hydrochloride (187 mg,1.29 mmol), and 30 ml of glacial acetic and was refluxed for 7.5 h. After cooling, the reaction mixture was poured on ice; alkalized with cone. NH40H and extracted with CH2Clz (3x60 ml). The combined organic layers were washed with HZO (3x80 ml) and brine (50 ml), dried over Na2S04 and evaporated. The residue (325 mg brownish foam) was converted into the methane sulfonate in the usual way and recrystallized from MeOH/diethyl ether to yield WO 95/31463 3o y ~'' - - PCT/SE95100503 264 mg (74%) of the title compound 15. Recrystallization of a small portion of this material from ethanol afforded an analytical sample. M.p. >256°C. FAB-MS: m/z 457 (M'+1 ),'H-NMR (DMSO-db): b 11.29, 9.17 and 8.45 (3 s, 'NH, NH, OH), 7.32 (d, J=8.2 Hz, 2 atom. H), 7.10 (t, J=8.2 Hz,1 atom. H), 6.94 (t, J=8.2 Hz, l atom. H), 6.59 (s, 2 atom. H), 5.90 (m, l olef. H), 5.68 (m, 2 olef. H),1.88 (s, CH3-C(5)), 0,55 (t, J=7.3 Hz, CH3). Analysis calculated for C29H3zNxOaH. 0.5 H20 (561.70): C
64.15, H
66.4, N 4.99, S 5.72; found: C 64.08, H 6.87, N 5.09, S 5.87.
Exam 1 Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-5-methyl-14-n-propyloxy-6,7-2,3'-indolomorphinan. CH3S03H (compound 18).
A mixture of 4,5a epoxy-3-methoxy-5-methyl-14-n-propyloxymorphinan-6-one hydrochloride (compound 12 of Example 7) (1.46 g, 3.7I mmol), potassium carbonate (2.24 g, 16.24 mmol), cyclopropylmethyl chloride (0.43 ml, 4.44 mmol), and 15 ml of anhydrous N,N-dimethyl formamide was stirred at 85°C (bath temperature) for 36 h. The inorganic solid was filtered off and the filtrate evaporated. A solution of the residue in 30 ml of Cl-izClz was washed with HZO
(3x30 mI), dried over NaZSO,~ and evaporated. The residue (1,69 g orange-yellow oil) was dissolved in diethyl ether and treated with ethereal HCl to give 920 mg (55%) of 17-(cyclopropylmethyl)-4,5a-epwcy-3-methoxy-5-methyl-14-n-propyloxymorphinan-6-one hydrochloride (compound 16) as colorless powder.
M.p. 156-158°C. IR (KBr): 3400 ('NH),1723 (CO) cml. CI-MS: m/z 412 (M'+1).'H
NMR (DMSO-db): 8 8.57 (s, 'NH), 6,85 (d, J=8.2 Hz, l atom. H), 6.75 (d, J=8.2 Hz, 1 atom. H), 3.79 (s, OCH3), L51 (s, CH3-C(5)), 0.97 (t, J=7.4 Hz, CH3). Analysis W095/31463 ~ ~ . . ~. , ,. PCTISE95100503 calculated for C~H33N04. HCI. 0.6 HBO (458.81): C 65.45, H 7.73, N 3.05, CI

7.73;
found: C 65.45, H 7.85, N 3.08, Cl 7.84.
A 1 M solution of boron tiibromide in CHzClz (7.3 ml) was added at once to an ice-cooled solution of the compound 16 (480 mg, 0.97 mmol) in 50 ml of CHZCIz.
After 50 min stirring at 0-5°C, a mixture of 13 g ice and 3 ml conc.
NH40H was added. The resulting mixture was stirred at room temperature for 30 min and the extracted with CHzCIz (3x30 ml). The combined organic layers were washed with brine (45 ml), dried over Na2S04 and evaporated. The residue (204 mg slightly brown foam) was treated with 0.5 ml hot MeOH to afford 302 mg (557°) of (cyclopropylmethyl)-4,5a-epoxy-3-hydroxy-5-methyl-14-n-propyloxymorphinan-6-one (compound 17). M.p. 184-186°C. IR (KBr): 3390 (OH), 1720 (CO)cm 1. CI-MS:
m/z 397 (M'+1).'H-NMR (CDC13): 810.24 (broad s, OH), 6.73 (d, J=8.2 Hz, I
arom.
H), 6.65 (d, J=8.2 Hz, 1 arom. H)1.62 (s, CH3 C(5)), 1.00 (t,J=7.3 Hz, CH3).
Analysis calculated for C24H3iNTOa. 0.6 MeOH (416.74): C 70.90, H 8.08, N 3.36; found:
C
70.76, H 7.73, N 3.52.
A mixture of rnmpound 17 (230 mg, 0.58 mmol), phenylhydrazine hydrochloride (142 mg, 0.98 mmol), and 23 m1 of glacial acetic add was refluxed for 3.5 h.
After cooling, the reaction mixture was poured on ice, alkalized with con. NH40H and extracted with CFizCiz (3x40 ml). The combined organic layers were washed with H20 2x50 ml) and brine (50 ml), dried and evaporated. The residue (262 mg yellow-brown foam) was converted in the usual way into the methane sulfonate and crystallized from MeOH/diethyl ether to yield 204 mg (6270) of the compound 18. M.p. 295-298 (dec.) FAB-MS: m/z 471 (M'tl).'H-NMR (DMSO-db) 811.27, 9.I2 and 8.46 (3s, 'NH, NH, OH), 7.14 (m, 4 arom. H), 6.59 (s, 2 arom.
H), 1.90 (s, CH3-C(5)), 0.67 (t, J=7.3 Hz, CH3) Analysis,'calculated for C3oH~NZ03.
CH3S03H. 1.5 H20 (584.74): C 62.71, H 6.96, N 4.72, S 5.40; found: C 62.67, H
6.96, N 4.79, S 5.40.
Examples 9-24, and 28-30 illustrate further compounds, which can be prepared according to one of the methods described above.
Example 9 17-(Cydopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-hydroxy-3-(methoxymethoxy)-6,7-2',3'-benzo[bJfuranomorphinan (compound 19).
M.p.i29-130°C. iH-NMR (CDC13): 8 7..15 (d, J = 8.3 Hz, 1 aiom. H), 7,37 (d, J = 8.3 Hz, l arom. H), 7.25 (m, l arom. H), 7.16 (m, 1 arom.), 6.86 (d, J = 8.3 Hz, l arom.
H), 6.60 (d, J = 8.3 Hz, 1 arom. H), 5.63 (s, H-C(5)), 5.17 and 5.06 (2 d, J =
6.6, 6.6 Hz, OCHZO), 3.42 (s, CH30).
Example 10 I7-Cyclopropylmethyl-6,7-dehydro-4,5a-epoxy-14-hydroxy-3-(methoxymethoxy)-6,7-2',3'-(N-methoxymethylindolo)morphinan (compound 20).
'H NMR (CDC13): & 7.44 (m, 2 arom. H), 7.20 (m, l arom. H), 7.07 (m, 1 arom.
H), 6.82 (d,J = 8 Hz, l arom. H), 6.58 (J = 8 Hz), 5.81 (s, H-C(5)), 5.79 and 5.50 (2 d, J =
10.8,10.8 Hz, NCH20), 5.12 and 550 (2 d, J = 6.4, 6.4 Hz, OCH20), 3,41 and 3.33 (2 s, 2 CH30).

Example 11 17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5a-epoxy-14-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan (compound 21).
M.p. 180-182 °C. 1H NMR (CDC13): b 7.41 (d, J = 8.3 Hz, 1 atom. H), 7.33 (d, J = 8.3 Hz, l atom. H), 7.23 (m, 1 atom. H) 7.14 (m, 2 atom. H), 7.03 and 7.01 (2 d, J
= 7.3, 7.3 Hz), 6.84 (d, J, 8.3 Hz, l atom: H) 6.59 (d, J = 8.3 Hz, 1 atom. H), 5.56 (s, H-C(5)), 5.32 and 4.68 (2 d, J = 8.7, 8.7 Hz, OCHZAr), 5.16 and 5.05 (2 d, J =
6.6, 6.6 Hz, OCHaO), 3.41 (S, cH3o).
Ex~le 12 17-(Cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5a-epoxy-3-hydroxy-6,7-2',3'-benzo[bJfuranomorphinan (compound 22).
M.p. 193-195 °C (dec). 1H NMR (CDC13): b 7.42 (d, J = 8.3 Hz, 1 atom.
H), 7.33 (d, J
= 8 Hz, 1 atom. H), 7.24 (m, l atom. H) 7.14 (m, 2 atom. H), 7.03 and 7.01 (2 d, J =
7.3 Hz, 1 atom. H), 6.64 (d, J, 8.1 Hz, l atom. H) 6.56 (d, J = 8.1 Hz, l atom. H), 5.58 (s, H-C(5)), 5.32 and 4.68 (2 d, J = 8.6 Hz, OCHZ Ar).
Exdmple 13 17 (CydopropyImethyl)-6,7-dehydro-4,5a-epoxy-3-(methoxymethoxy)-14-(3'-nitrobenzyloxy)-6,7-2',3'-benzo[bJfuranomorphinan (compound 23).
'H NMR (CDC13): & 8.25 (s, l atom. H), 7.28 (m, 4 atom. H), 7.15 (m, 1 atom.
H) 6.87 (d, J = 8.3 Hz, I atom. H), 6.62 (d, J = 8.3 Hz, 1 atom. H), 5.66 (s, H-C(5)), 5.17 2I89~.~~
WO 95131463 ~ PCTISE95/00503 r and 5.07 (2 d, J =6.6 Hz; OCH20) 4.92 and 4.44 (2 d, J = 11.5 Hz, OCHZAr), 3.42 (s, CH3O).
Example 14 17-(Cyclopropylmethyl)-6,7-dehydro-4,Sa-epoxy-3-hydroxy-14-(3'-nitrobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride (compound 24).
M.p. > 230 °C (dec). 1H NMR (DMCO-d6): & 9.40 (s, OH), 9.15 (broad s, ~NH), 7.84 (s, 1 atom. H) 7.60 (d, J = 8.8 Hz, l atom. H), 7.53 (d, J = 7.6 Hz, l atom.
H), 7.45 (d, J = 8 Hz, i atom. H) 7.23 (d, J = 7.6 Hz, 1 atom. H), 7.19 (d, J = 7.6 Hz, 1 atom.
H), 6.98 (m, l atom. H) 6.88 (d, J = 7.6 Hz, l atom. H) 6.69 (d, J =8.3 Hz, 1 atom.
H), 6.6fi (d, J = 8.3 Hz, l atom. H), 6.03 (s, H-C(5)), 4.98 and 4.87 (2 d, J
= 14, 14 Hz, OCHzPh).
Example 15 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a.-epoxy-3-(methoxymethoxy)-14-(2-naphtylmethoxy)-6,7-2'-3'-benzo[b]furanmorphinan (compound 25).
M.p. 198-20I °C. 1H NMR (CDCI~): S 7.72-7.08 (m, ll atom. H); 6.86 (d, J = 8.3 Hz, 1 atom. H), 6.62 (d, J = 8.3 Hz, l atom. H), 5.68 (s, H-C(5)), 5.17 and 5.07 (2 d, J =
6.6, 6.6 Hz, OCHZO), 5.01 and 4.57 (2 d, J =11.2,11.2 Hz, OCH2Ar), 3,42 (s, CH30).

Exam In a 16 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(2'-naphtylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride (compound 5 26).
M.p. > 215 °C. 1H NMR (DMSO-d6): 8 9.42 (s, OH), 9.00 (broad s, ~NH), 7.68-6.85 (m, 11 arom. H), 6.71 (d, J = 8 Hz, 1 arom. H), 6.67 (d, J = 8 Hz, 1 arom. H), 6.04 (s, H-C(5)), 4.92 (s, OCH2Ar).
ExaT . _ 17-(Cydopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-(2'-fluorobenzyloxy)-3-(methoxymethoxy)-6,7-2'-3'-benzo[b]furanmorphinan (compound 27).
'H NMR (DMSO-d6): b 7.56 (d, J = 8 Hz, l arom. H), 7.49 (d, J = 8 Hz, l arom.
H), 7.32 (m, 1 arom. H), 7.21 (m, I arom . H), 6.81 (d, J = 8.4 Hz, l arom. H), 6.67 (d, J
= 8.4 Hz), 5.72 (s, H-C(5)), 5.06 and 5.01 (2 d, J = 6.4, 6.4 Hz, OCH20), 4.89 and 4.57 (2 d, J = 11.6,11.6 Hz, OCHZ Ar), 3,33 (s, CH30).
ple 18 I7-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-(2'-fluoro-benzyloxy)-3 hydroxy-6,7-2',3'-benzo[b]furanomorphinan Hydrochloride (compound 28).
M.p. > 2I5 °C. 1H NMR (CDC13): & 9.45 (s, OH), 9.04 (broad s, ~NH), 7.54 (d, ] _ 8.4 Hz, 1 arom. H) 7.31-6.73 (m, 7 arom. H), 6.71 (d, J = 8.2 Hz, 2 arom. H), 6.66 (d, J = 8.2 Hz, l arom. H), 5.98 (s, H-C(5)), 4.81 and 4.84 (2 d, J = I2 Hz, OC132 Ar).

WO 95131463 ' PCTlSE95100503 Example 19 14-Cinnamyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5a epoxy-3-(methoxymethoxy)-6,7-2'-3'-benzo[b]furanomorphinan (compound 29).
M.p. 156-159 °C. 1H NMR (CDC13): 8 7.47 (d, J = 8 Hz, l arom. H), 7.33 (d, J = 8 Hz, l arom. H), 7.28-7.07 (m, 7 arom. H), 6.84 (d, J = 8.4 Hz, l arom. H), 6.59 (d, J
= 8.4 Hz, l arom . H), 6.38 (d, J =16 Hz,1 olef. H), 6.13 (m, l olef. H), 5.68 (s, H-C(5)), 5.16 and 5.06 (2 d, ] = 6.4, 6.4 Hz, OCH20), 4.46 and 4.11 (2 m,OCH2Ar), 3,42 (s, CH30).
Exa-male 20 14-Cinnamyloxy-17-cyclopropylmethyl-6,7-dehydro-4,5a-epoxy-3-hydroxy-6,7-2'-3'-benzo[b]furanomorphinan Salicylate (compound 30).
1H NMR (CDC13): 8 7.94 (d, J = 8 Hz, i arom. H), 7.35 (d, J = 8 Hz, l arom.
H), 7.30-6.73 (m,12 arom. H), 6.56 (d, J = 8 Hz, l arom. H), 5.96 (s, 2 olef. H), 5.55 (s, H-C(5)), 4.33-4.02 ( m, OCHZAr).
Example 21 -__ 17-(Cydopropylmethyl}-6,7-dehydro-4,5a-epoxy-14-methoxy-3-(methoxymethoxy)-6,7-2'-3'-benzo(b]furanomorphinan (compound 31).
'H NMR (DMSO-d6): b 7.7.56 (d, J = 8 Hz, l arom. H), 7.52 (d, J = 8 Hz, l arom.
H), 7.32 (dd, J = 8, 8 Hz, l arom. H), 5.64 (s, H-C(5)), 5.05 and 5.00 (2 d, J
= 6.4, 6.4 Hz, CEO). 3.32 (CH30).

WO 95/31463 . ' ~ PCTISE95100503 Example 22 __ 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-methoxy-6,7-2'-3'-benzo[b]furanomorphinan hydrochloride (compound 32).
M.p. > 240 °C.'H NMR (DMSO-d6): b 9.47 (s, OH), 9.17 (broad s, +NH), 7.61 (d, J
= 8 Hz, 1 arom. H), 7.53 (d, J -- 8 Hz, 1 arom. H), 7.36 (dd, J = 8, 8 Hz, i arom. H), 7.27 (dd, J = 8, 8 Hz, l groin. H), 6.72 (d, J = 8.4 Hz, 1 arom. H), 6.65 (d, J = 8.4 Hz, 1 arom. H), 5.90 (s, H-C(5)), 3.35 (s, CH30).
Example 23 17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5a-epoxy-3-(methoxymethoxy)-6,7-2'-3'-~T-methoxymethylindolo)morphinan (compound 33).
'H NMR (CDC13): 8 7.56 (m, 1 arom. H), 7.44 (m, 1 arom. H), 7.37-7.17 (m, 3 arom .
H), 7.01 (m, l arom. H), 6.91 (m, 1 arom. H), 6.83 (d, J = 8.2 Hz, 1 arom. H), 6.59 (dd, J = 8.2, 8.2 Hz, l arom. H), 5.90 (s, H-C(5)), 5.82 and 5.55 (2 d, J =
11.2,11.2 Hz, NCHzO), 5.13 and 5.03 (2 d, J = 6.4, 6.4 Hz, OCHZO), 4.98 and 4.56 (2 d, J
= 13, 13 Hz, OCHzAr), 3.40 and 3.26 (2 s, 2 CH30).

" t ', ~ ' PCTISE95100503 , t W0 95131463 3$
)example 24 17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5a-epoxy-3-hydroxy-6,7-2'-3'-indolomorphinan hydrochloride (compound 34).
M.p. > 250 °C (dec). 1H NMR (DMSO-d67: 811.38 (s, NH), 9.38 (s, OH), 8.76 (broad s, ~NH), 7.34-6.85 (m, 8 arom. H), 6.72 (d, J = 8 Hz, I arom. Ice, 6.64 (d, J =
8 Hz, l arom. H), 5.93 (s, H-C(5)), 4.80 and 4.67 (2 d, J =13,13 Hz, OCHZ Ar).
Example 25 Synthesis of I7-(Cyclopropylmethyl)-6,7-dehydro-3,14-dimethoxy-4,5a-epoxy-6,7-2'-3'-benzo[bjfuranomorphinan (compound 35).
Sodium hydride (144 mg, 6 mmol; obtained from 240 mg of 60% sodium hydride dispersion in oil by washings with n-hexane) was added to a solution of naltriben methanesulfonate (P.S. Portoguese et al., J. Med. Chem., Vol. 34: 1715-1720,1991) 500 mg, 0.97 mmol) in 10 ml of anhydrous N,N-dimethyl-formamide at 0 °C. The resulting mixture was stirred at 0 °C for 15 min and then at room temperature for another 30 min. After cooling to 0 °C, dimethyl sulfate (380 ul, 4 mmol) was added and stirring was continued at first at 0 °C for 30 min and then at room temperature for 3 h. Excess sodium hydride was destroyed by addition of MeOH
and HzO. The resulting mixture was extracted with ethyl acetate (3 x 40 ml), the combined organic layers were washed with H20 (2 x 30 ml) and brine (2 x 30 ml), dried over NaZS04 and evaporated to give a crystalline residue which was recrystallized from MeOH to afford 320 mg (74 %) of compound 35. M.p. 221-224 °C (dec).1H NMR (CDC13): 87.47-7.14 (m, 4 arom. H), 6.64 (d, J =8.4 Hz,1 arom.

~ ', ' PCTISE95100503 H), 6.59 (d, J = 8.4 Hz, 1 arom . I-3), 5.62 (s, H-C(5)), 3.78 (s, CH30-C(3)), 3.3I (s, CH3o-c(14)).
Examp a 26 Synthesis of 17-Cyclopropylmethyl-6,7-dehydro-4,5a-epoxy-14-hydroxy-6,7-2',3'-benzo[b]furanomorphinan (compound 36).
A mixture of 3-deoxyonaltrexone (R. Krassrug and H. Schmidhammer, Heterocycles, Vol. 38: 877-881,1994) (1,3 g, 3.99 mmol), O-phenylhydroxylamine hydrochloride (750 mg, 5.15 mmol), methanesulfonic acid (0.75 ml, 11.55 mmol), and ethanol (30 ml) was refluxed for 20 h. After cooling, the mixture was diluted with HzO, alkalized with cone. NH40H and extracted with CH2CIz (4 x 40 ml).
The combined organic layers were washed with H20 (2 x 30 ml) and brine (30 ml), dried over NaZS04 and evaporated to give a brownish oil which was crystallized form MeOH to yield 1.1 mg (69 qo) of compound 36. M.p. > 260 °C.'H NMR
(CDC13): b 7.45 (d, J = 8 Hz, 1 arom. H), 7.37 (d, J = 8 Hz, I arom. H), 7.26-7.13 (m, 2 arom. H), 7.01 (dd, J = 7.8, 7.8 Hz, l arom. H), 6.67 (d, J = 7.8 Hz, I
arom. H), 6.59 (d, J = 7.8 Hz, 1 arom. H), 5.59 (s, H-C(5)), 5.00 (broad s, OH).
Synthesis of 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-hydroxy-6,7-2'-3'-indolomorphinan hydrochloride (compound 37).
A mixture of 3-deoxyonaltrexone (R. Krassnig and H. Schmidhammer, Heterocycles, Vol. 38: 877-881,1994) (1,5 g, 4.6 mmol), phenylhydrazine hydrochloride (1.0 mg, 6.9 mmol),1M HCl in ether (5 ml), and methanol (20 ml) was stirred at room temperature for 3 days. After concentration to ca. half of the original volume in vacuo, the solution was refrigerated overnight. The colorless crystals formed were collcted to yield 1.54 g (77 %) of compound 37. M.p. >
240 °C
(dec.). 1H NMR (DMSO-d6): b 1L37 (s, NH), 9.01 (broad s, ~NH), 7.36-6.94 (m, 5 5 arom. H), 6.78 (d, J = 7:8 Hz, l arom. H), 6.59 (d, J = 7.8 Hz, l arom. H), 6.55 (s, OH).
Example 28 10 17(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(3'-chlorobenzyloxy)-6,7,2',3'-benzo[b]furanomorphinan, hydrochloride (compound 39).
'H NMR (DMSO-d6): & 9.40 (s, OH), 8.59 (broad s, +NH), 7.53-6.90 (m, 8 arom.
H), 15 6.65 (s, 2 arom. H}, 6.03 (s, H-C(5)), 4.74 and 4.62 (2 d, J=13.6,13.6 Hz, OCHz(3'-ClPh)}. Analysis calculated for C33H3oC1N04. HCI. 1.5 H20: C 65.67, H 5.68, N
2.32; found: C 65.31, H 5.37, N 2.33.
Example 29 17-(Cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-14-(2'-chlorobenzyloxy)-6,7,2',3'-benzo[b]furanomorphinan Hydrochloride (compound 41).
M.p. > 220°C.'H NMR (DMSO-d6): & 9.40 (s, OH), 8.59 (broad s, +NH), 7.56-6.90 (m, 8 arom. H), 6.66 (rri, 2 arom. H), 6.03 (s, H-C(5)), 4.74 (s, OCHZ(2-ClPh)).
Analysis calculated for C33H3oC1NO4. Hcl. 1.5 H20: C 65.67, H 5.68, N, 2.32.
Found: C 65.72, H 5.48, N 2.25.

W095/31463 ~ PCT/SE95/00503 Example 30 14-Allyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-3-hydroxy-i'-allyl-6,7-2',3'-indolomorphinan hydrochloride (compound 42).
NMR of the free base (colorless oil) 'H NMR (CDCI3): 8 7.40 (d, J = 8.4 Hz, 1 arom. H), 7.24 (m, l arom. H), 7.i5 (m, i arom. H), 7.03 (m, l aroni. H), 6:57 (d, J = 8.4 Hz, l arom. H), 6.50 (d, J =
8.4 Hz, 1 arom. H), 6.08 (m,1 olef. H), 5.76 (m, 1 olef. H), 5.72 (s, H-C(5)), 5.15-4.75 (m, 6 H, CHZN,2 CHZ = C), 4.24 and 3.92 (2 dd, J = 12.4, 4.8 Hz, CHzO).
This free base was dissolved in ethyl ether and treated v~-ith HCl/ether solution HCl at 0°C. Isolation of the precipitate provided the title compound 42 as a solid.
Pharmaceutical Rr~parations For the preparation of a pharmaceutical formulation, the active ingredient may be formulated to an injection, capsule, tablet, suppository, solution or the like. Oral formulaiion and injection are preferably employed. The pharmaceutical formulation may comprise the 8-selective antagonist alone or may also rnmprise expedients such as stabilizers, buffering agents, diluents, isotonic agents, antiseptics and the like. The pharmaceutical formulation may contain the above described active ingredient in the amount of 1-95 9° by weight, preferably 10-60 %
by weight. The dose of the active ingredient may be appropriately selected depending on the objects of administration, administration route and conditions of the patients. The active ingredient may be administered in doses between 1 mg and 1 g per day in case of administration by injection and in doses between IO
mg and 5 g per day in case of oral administration. The preferred dose for injection is 20-500 mg per day.

Biol~ical studies &-Antagonism was assessed using the electrical stimulated guinea-pig ileum longitudinal muscle preparation (GPI; containing It and x opioid receptors) and mouse vas deferens preparation (MVD; containing ~, x and 8 opioid receptors) (H.
Schmidhammer et al., J. Med. Chem., Vol. 32: 418-421,1989; H Schmidhammer et al., J. Med. Chem., Vol. 33: 1200-1206,1990). The activity of the compound 1 of the Examples for inhibiting the suppression of contraction of the organs by three receptor selective agonists (DAMGQ, lt; Cl 977, x; DPDPE, b) was measured. The compound exhibited &selective opioid antagonism with very good lt/8 and x/8 selectivity ratios.
Conclusion The pharmacological studies of the novel morphinan derivatives of formula (I) of the present invention have shown that these compounds have selectivity for b opioid receptors and are effective as opioid antagonists.

Claims (76)

CLAIMS:

1. ~A compound according to the formula (I) wherein R1 represents C2-C10 alkenyl; C4-C10 cycloalkylalkyl wherein the cycloalkyl is cycloalkyl and the alkyl is C1-C4 alkyl; C4-C10 cykloalkenylalkyl wherein the cycloalkenyl is C3-C6 cykloalkenyl and the alkyl is C1-C4 alkyl; C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl; or C8-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl;

R2 represents hydrogen, hydroxy, C1-C6 alkoxy; C2-6 alkenyloxy; C7-C16 arylalkyloxy wherein the aryl is C6-C10 aryl and the alkyloxy is C1-C6 alkyloxy; C7-C16 arylalkenyloxy wherein the aryl is C6-C10 aryl and the alkenyloxy is C2-C6 alkenyloxy; C1-C6 alkanoyloxy; or C7-C16 arylalkanoyloxy wherein the aryl is aryl and the alkanoyloxy is C1-C6 alkanoyloxy;

R3 represents hydrogen, C1-C6 alkyl; C2-C6 alkenyl; C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl; hydroxy(C1-C6)alkyl;
alkoxyalkyl wherein the alkoxy is C1-C6 alkoxy and the alkyl is C1-C6 alkyl; or CO2H;
CO2(C1-C6 alkyl);

R4 is hydrogen, hydroxy; C1-C6 alkoxy; C7-C16 arylalkyloxy wherein the aryl is C10 aryl and the alkyloxy is C1-C6 akyloxy; C2-C6 alkenyloxy; C1-C6 alkanoyloxy;
C7-C16 arylalkanoyloxy wherein the aryl is C6-C10 aryl and the alkanoyloxy is C6 alkanoyloxy; or C2-C10 alkyloxyalkoxy wherein alkyloxy is C1-C4 alkyloxy and alkoxy is C1-C6 alkoxy;

R5 and R6 each independently represent hydrogen; OH; C1-C6 alkoxy; C1-C6 alkyl;
hydroxyalkyl wherein the alkyl is C1-C6 alkyl; halo; nitro; cyano;
thiocyanato;
trifluoromethyl; CO2H; CO2(C1-C6 alkyl); CONH2; CONH(C1-C6 alkyl); CON(C1-C6 alkyl)2; amino; C1-C6 monoalkyl amino; C1-C6 dialkyl amino; C1-C6 cyhloalkyl amino; SH; SO3H; SO3(C1-C6 alkyl); SO2(C1-C6 alkyl); SO2NH2; SO2NH(C1-C6alkyl); SO2NH (C7-C20 arylalkyl); or SO(C1-C6 alkyl); or R5 and R6 together form a phenyl ring which is unsubstituted or substituted by halo, nitro, cyano, thiocyanato; C1-C6 alkyl; trifluoromethyl; C1-C6 alkoxy, CO2H, CO(C1-C6 alkyl), amino, C1-C6 monoalkylamino, C1-C6 dialkylamino, SH; SO3H; H; SO3(C1-C6 alkyl), SO2(C1-C6 alkyl), or SO(C1-C6 alkyl), and X represents oxygen; sulfur; NCH = CH or NR9 wherein R9 is H, C1-C6 alkyl, C2-alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-alkyl, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is alkenyl; or C1-C6 alkanoyl;

and wherein aryl is unsubstituted or mono- or di- or trisubstituted independently with hydroxy, halo, nitro, cyano, thiocyanato, trifluoromethyl, C1-C3 alkyl, C1-C3 alkoxy, CO2H, CO2 (C1-C3)alkyl, CONH2, CONH(C1-C3 alkyl), CON(C1-C3 alkyl), CO (C1-C3 alkyl), amino, (C1-C3 monoalkyl) amino, (C1-C3 dialkyl) amino, C5-C6 cycloalkylamino (C1-C3 alkanoyl) amino, SH, SO3H, SO3 (C1-C3 alkyl), SO2 (C1-C3 alkyl), SO(C1-C3 alkyl), C1-C3 alkylthio or C1-C3 alkanoylthio; and with the followiong provisos:

(i) when R2 is hydroxy, R3 cannot be hydrogen, except when R4 is hydrogen, OCH2OCH3, OCH2OC2H5 or OC(Ph)3; or (ii) R3 may only be hydrogen when R4 is C2-C10 alkyloxyalkoxy, and/or when R2 is C7-C16 arylalkylkoxy, C7-C16 arylalkenyloxy or C2-C6 alkenyloxy;

or pharmacologically acceptable salt thereof.

2. A compound or salt according to claim 1, wherein R1 is selected from allyl, cinnamyl, cyclopropylmethyl and cyclobutymethyl;

R2 is selected from methoxy, ethoxy, n-propyloxy, benzyloxy and benzyloxy substituted in the aromatic ring with F, Cl, NO2, CN, CF3, CH3 or OCH3;

allyloxy, cinnamyloxy or 3-phenylpropyloxy;

R3 is selected from hydrogen, methyl, ethyl, benzyl and allyl;

R4 is selected from hydroxy, methoxy, methoxymethoxy and acetyloxy;

R5 and R6 are each and independently selected from hydrogen;
nitro; cyano; chloro, fluoro, bromo trifluoromethyl; CO2H;
CO2 CH3; CONH2; CONH CH3; SH; SO2NH2; N(CH3)2; and SO2CH3; and X is selected from oxygen; NH, N CH3, N-benzyl and allyl.

3. ~A compound according to claim 1 or 2, in form of a pharmaceutically acceptable salt.

4. ~A compound according to claim 1 or 2, wherein the salt is an inorganic salt.

5. ~A compound according to claim 1 or 2, wherein the salt is an organic salt.

6. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5a-epoxy-14-ethoxy-3-hydroxy-5-methyl-6,7-2',3'-indolomorphinan × HCl.

7. ~17-allyl-6,7-dehydro-4,5.alpha.-epoxy-14-ethoxy-3-hydroxy-5-methyl-6,7-2',3'-indolomorphinan × HCl.

8. ~6,7-dehydro-4,5.alpha.-epoxy-14-ethoxy-3-hydroxy-5-methyl-17-(2-phenyl)ethyl-6,7-2',3'-indolomorphinan × HCl.

9. ~17-allyl-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-methoxy-5-methyl-6,7-2',3'-indolomorphinan × HCl.

10. ~6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-methoxy-5-methyl-17-(2-phenyl)ethyl-6,7-2',3'-indolomorphinan × HCl.

11. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-methoxy-5-methyl-6,7-2',3'-indolomorphinan × HCl.

12.~17-allyl-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-5-methyl-14-n-propyloxy-6,7-2',3'-indolomorphinan × CH3SO3H.

13. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-5-methyl-14-n-propyloxy-6,7-2',3'-indolomorphinan × CH3SO3H.

14. ~17-(cyrclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan.

15. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-3-(methoxymethoxy)-6,7-2',3'-(N-methoxymethylindolo)morphinan.

16. ~17-(cyclopropylmethyl)-6,7-dehydro-74-(2',6'-dichlorobenzyloxy)-4,5.alpha.-epoxy-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan.

17. ~17-(cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5.alpha.-epoxy-3-hydroxy-6,7-2',3'-benzo[b]furanomorphinan.

18. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-(methoxymethoxy)-14-(3'-nitrobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan.

19. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(3'-nitrobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan × HCl.

20. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-(methoxymethoxy)-14-(2'-naphthylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan:

21. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(2'-naphtylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan × HCl.

22. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-(2'-fluorobenzyloxy)-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan.

23. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-(2'-fluorobenzyloxy)-3-hydroxy-6,7-2',3'-benzo[b]furanomorphinan × HCl.

24. ~14-cinnamyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-(methoxymethoxy)-6,7-2',3'-benzo[b]furanomorphinan.

25. ~14-cinnamyloxy-17-(cydopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-6,7-2',3'-benzo[b]furanomorphinan salicylate.

26. ~17-(cydopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-methoxy-3-(methoxmethoxy)-6,7-2',3'-benzo[b]furanomorphinan.

27. ~17-(cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5.alpha.-epoxy-3-(methoxy-methoxy)-6,7-2',3'-(N-methoxymethylindolo)morphinan.

28. ~17-(cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-6,7-2',3'-indolomorphinan × HCl.

29. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-6,7-2',3'-benzo[b]furanomorphinan.

30. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-6,7-2',3'-indolomorphinan × HCl.

31. ~17-(cyclopropypmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(3'-chlorobenzyloxy)-6,7-2',3'- benzo[b]furanomorphinan × HCl.

32. ~17-(cyclopropypmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(2'-chlorobenzyloxy)-6,7-2',3'- benzo[b]furanomorphinan × HCl.

33. ~14-allyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-1'-allyl-6,7-2',3'-indolomorphinan × HCl.

34. ~17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-ethoxy-3-hydroxy-5-methyl-~
6,7-2',3'-indolomorphinan hydrochloride.

35. ~17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-methoxy-methyl-6,7-2',3'indolomorphinan hydrochloride.

36. ~17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-5-methyl-14-n-propyloxy-6,7-2,3'-indolomorphinan CH3SO3H.

37. ~17-(cyclopropylmethyl)-6,7-dehydro-14-(2',6'-dichlorobenzyloxy)-4,5.alpha.-epoxy-3-hydroxy-6,7-2',3'-benzo(b]furanomorphinan.

38. 17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(3'-nitrobenzyloxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride.

39. 17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(2'-naphtylmethoxy)-6,7-2',3'-benzo[b]furanomorphinan hydrochloride.

40. 17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-(2'-fluorobenzyloxy)-3-hydroxy-6,7-2',3'-benzo[b]furanomorphinan hydrochloride.

41. 14-Cinnamyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-6,7-2'-3'-benzo[b]furanomorphinan salicylate.

42. 17-(Cyclopropylmethyl)-14-(2'-chlorobenzyloxy)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-6,7-2'-3'-indolomorphinan hydrochloride.

43. 17-Cyclopropylmethyl-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-6,7-2',3'-benzo[b]furanomorphinan.

44. 17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-14-hydroxy-6,7-2'-3'-indolomorphinan hydrochloride.

45. 17(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(3'-chlorobenzyloxy)-6,7,2',3'-benzo[b]furanomorphinan hydrochloride.

46. 17-(Cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-14-(2'-chlorobenzyloxy)-6,7,2',3'-benzo[b]furanomorphinan hydrochloride.

47. 14-Allyloxy-17-(cyclopropylmethyl)-6,7-dehydro-4,5.alpha.-epoxy-3-hydroxy-1'-allyl-6,7-2',3'-indolomorphinan hydrochloride.

48. A compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for use as an immunosuppressive agent.

49. A compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for use as an analgesic.

50. A compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 7 to 47 for use as a brain-cell protectant following a central nervous system injury.

51. A compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for treatment of a rheumatic disease.

52. A compound or salt according to claim 51, wherein the rheumatic disease is rheumatoid arthritis.

53. A compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for suppressing rejection of a transplanted organ.

54. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 as an immunosuppressive agent.

55. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 as an analgesic.

56. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 as a brain-cell protectant following a central nervous system injury.

57. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for treatment of a rheumatic disease.

58. Use according to claim 57, wherein the rheumatic disease is rheumatoid arthritis.

59. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 for suppressing rejection of a transplanted organ.

60. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 in manufacture of an immunosuppressive agent.

61. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 in manufacture of an analgesic.

62. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 in manufacture of a brain cell protectant following a central nervous system injury.

63. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 in manufacture of a medicament for treatment of a rheumatic disease.

64. Use according to claim 63, wherein the rheumatic disease is rheumatoid arthritis.

65. Use of a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 in manufacture of a medicament for suppressing rejection of a transplanted organ.

66. A pharmaceutical composition comprising a compound or salt according to any one of claims 1 to 5 or a compound according to any one of claims 6 to 47 and a pharmaceutically acceptable carrier.

67. A pharmaceutical composition according to claim 66 for use as an immunosuppressive agent.

68. A pharmaceutical composition according to claim 66 for use as an analgesic.

69. A pharmaceutical composition according to claim 66 for use as a brain-cell protectant following a central nervous system injury.

70. A pharmaceutical composition according to claim 66 for treatment of a rheumatic disease.

71. A pharmaceutical composition according to claim 70, wherein the rheumatic disease is rheumatoid arthritis.

72. A pharmaceutical composition according to claim 66 for suppressing rejection of a transplanted organ.

73. A process for the preparation of a compound of the formula I according to claim 1, wherein i) thebaine of the formula is treated with a dialkylsulfate, a fluorosulfonic acid alkyl ester, an alkylsulfonic acid alkyl ester, an arylsulfonic acid alkylester, an alkyl halide, an aralkyl halide, an alkylsulfonic acid aralkyl ester, an arylsulfonic acid aralkyl ester, an arylalkenyl halide, or a chloroformate, giving a compound according to formula (II) wherein R is C1-C6 alkyl; C2-C6 alkenyl; C7-C16 aralkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C1-C6 alkoxy and the alkyl is C1-C6 alkyl; or CO2 (C1-C6 alkyl) ;

ii) (II) is reacted with performic acid or m-chloroperbenzoic acid at a temperature in the range 0-60°C
yielding iii) (III) is treated with a dialkyl sulfate, an alkyl halide, an alkenyl halide, an aralkyl halide, an arylalkenyl halide, or a chloroformate, using a strong base giving a compound according to formula (IV) wherein R1 is C1-C6 alkyl, C2-C6 alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl, C1-C6 alkanoyl, C7-C20 arylalkanoyl wherein the aryl is C6-C14 aryl and the alkyl is C1-C6 alkyl , or C7-C20 arylalkenoyl wherein the aryl is C6-C14 aryl and the alkenoyl is C2-C6 alkenoyl;

R2 is hydrogen; C1-C6 alkyl; C2-C6 alkenyl C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl; alkoxyalkyl wherein the alkoxy is C1-C6 alkoxy and the alkyl is C1-C6 alkyl; or CO2 (C1-C6alkyl) ;

iv) catalytic hydrogenation of (IV) yields a compound according to formula (V) wherein R1 and R2 are as defined above in formula (IV);

v) (V) is N-demethylated, giving a compound according to formula (VI) wherein R1 and R2 are as defined above; and R1 is CO2CHC1CH3, CO2CH=CH2, CO2CH2CCI3, CO2CH2CH3, CO2Ph or CN;

vi) (VI) is cleaved giving a compound according to formula (VII) wherein R1 and R2 are as defined above in formula (V);

vii) compound (VII) is alkylated, yielding a compound according to formula (VIII) wherein R1 and R2 are as defined above in formula (V); and R3 represents C2-C6 alkenyl; C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl; C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is C2-C6 alkenyl; C4-C10 cycloalkylalkyl wherein the cycloalkyl is C3-cycloalkyl and the alkyl is C1-C4 alkyl; alkyl; or C4-C10 cycloalkylalkenyl wherein the cycloalkenyl is C3-C6 cycloalkenyl and the alkyl is C1-C4 alkyl;

viii) ether cleavage of (VIII) is performed, giving a compound according to formula (IX) wherein R1, R2 and R3 are as defined above;

ix) (IX) is alkylated or acetylated, giving a compound according to formula (X) wherein R1, R2 and R3 are as defined above; and R4 is hydrogen, C1-C6 alkyl, C7-C16 aralkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkyl, C2-C6 alkenyl, C7-C16 arylalkenyl wherein the aryl is C6-aryl and the alkenyl is C2-C6 alkenyl; C1-C6 alkanoyl; C7-C16 arylalkanoyl wherein the aryl is C6-C14 aryl and the alkanoyl is C1-C6 alkanoyl or C2-C10 alkyloxyalkyl wherein alkyloxy is C1-C4 alkyloxy and alkyl is C1-C6 alkyl, x) (IX) or (X) is reacted with phenylhydrazine or substituted phenylhydrazine giving a compound according to formula (I) wherein R1, R2, R3 and R4 are as defined above and X is NH;

R5 and R6 each independently represent hydrogen; OH; C1-C6 alkoxy; C1-C6 alkyl;
hydroxyalkyl wherein the alkyl is C1-C6 alkyl; halo; nitro; cyano;
thiocyanato;
trifluoromethyl; CO2H; CO2(C1-C6 alkyl); CONH2; CONH(C1-C6 alkyl); CON(C1-C6 alkyl)2; amino; C1-C6 monoalkyl amino; C1-C6 dialkyl amino; C5-C6 cycloalkylamino; SH; SO3H; SO3(C1-C6 alkyl); SO2(C1-C6 alkyl); SO2NH2;
SO2NH(C1-C6 alkyl); SO2NH (C7-C20 arylalkyl); or SO(C1-C6 alkyl); or R5 and R6 together form a phenyl ring which is unsubstituted or substituted by halo, nitro, cyano, thiocyanato; C1-C6 alkyl; trifluoromethyl; C1-C6 alkoxy, CO2H, CO(C1-C6 alkyl), amino, C1-C6 monoalkylamino, C1-C6 dialkylamino, SH; SO3H;
SO3(C1-C6 alkyl), SO2(C1-C6 alkyl), or SO(C1-C6 alkyl), and X represents oxygen; sulfur; CH = CH, or NR9 wherein R9 is H, C1-C6 alkyl, C2-alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-alkyl, C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and the alkenyl is alkenyl; or C1-C6 alkanoyl, with the proviso that when R2 is hydroxy R3 cannot be hydrogen, except when R4 is hydrogen, OCH2OCH3, OCH2OC2H5 or OC (Ph)3 xi) (IX) or (X) is reacted with O-phenylhydroxylamine or substituted O-phenylhydroxylamine, giving a compound according to formula (I) wherein R1, R2, R3, R4 and R5 are as defined above and X is O;

xii) thebaine is converted to 14-hydroxy codeinone according to formula (I) which in turn is converted to a compound according to formula (I) wherein R3 is H in essentially the same way as described for the 5-substituted series of compounds;

xiii) a compound of the formula (II) wherein R is as defined above or hydrogen is reduced by catalytic hydrogenation followed by acid hydrolysis (s. Boden et al., J. Org. Chem., Vol. 47: 1347-1349, 1982) to give a compound of formula (XI) wherein R is as defined above in formula (II) or hydrogen, which in turn is converted to a compound according to formula (I) wherein R2 is H, in essentially the same way as described for the 14-substituted series of compounds;

xiv) a compound of the formula (I) wherein R4 is hydrogen is prepared from a compound of the formula (IX) by allylation with 5-chloro-1-phenyl-1H-tetrazole, giving a phenyltetrazolyl ether of the formula (XII) wherein R2 and R3 are as defined above, R1 is as defined above or is CH3, and T is phenyltetrazolyl;
xv) catalytic hydrogenation of (XII) affords a compound of the formula (XIII) wherein R2 and R3 are as defined above, and R1 is as defined above or is CH3, with the proviso that when R3 is CH3 the N-methyl group is removed and the nitrogen alkylated as described above;
xvi) (XIII) is converted to a compound according to formula (I) wherein R4 is hydrogen and R1, R2, R3, R5 and R6 are as defined above, in the same manner as described for 3-substituted derivatives above;
xvii) a compound of formula (I) wherein R1 represents allyl or cyclopropylmethyl and R3 represents H is obtained starting either from naloxone (XIVa) or naltrexone (XIVa).

(XIVa): Naloxone - R is allyl (XIVb): Naltrexone - R is cyclopropylmethyl ;
whereby the 3-hydroxy group of a compound of formula (XIV) is protected by alkylation with benzyl bromide, methoxymethyl bromide, ethoxymethyl bromide or trityl chloride (triphenylmethyl chloride) in a solvent in the presence of a base to yield a compound of formula (XV) wherein R is allyl or cyclopropylmethyl and Y = CH2Ph, CH2OCH3, CH2OC2H5 or C(Ph)3;

when said compound is alkylated, alkenylated, cycloalkylalkylated, arylalkylated or arylalkenylated with a dialkyl sulfate, an alkyl halide, an alkenyl halide, an arylalkyl halide or an arylalkenyl halide in a solvent using a strong base 6-0,14-0-dialkylated compounds of formula (XVI) are formed wherein R1 is allyl or cyclopropylmethyl; and R2 is C1-C6 alkyl, C2-6 alkenyl, C7-C16 arylalkyl wherein the aryl is C6-C10 aryl and the alkyl is C1-C6 alkoxy or C7-C16 arylalkenyl wherein the aryl is C6-C10 aryl and alkenyl is C2-C6 alkenyl; and Y as defined above; said compound, is hydrolized in a diluted acid to afford a compound of formula (XVII) wherein R1 is allyl or cyclopropylmehtyl; and R2 is as defined above (formula XVI);

xviii) the carbonyl group in 6-position of naloxone of the formula (XIVa) and naltrexone of the formula (XIVb) respectively, is protected at a temperature between 20 and 200°C, giving a ketal of the formula (XVIII) wherein R is allyl or cyclopropylmethyl;
xix) the 3-hydroxy group in (XVIII) is protected by alkylation with benzyl bromide, methoxymethyl bromide, ethoxy methyl bromide or trityl chloride, giving a compound according to formula (XIX) wherein R is allyl or cyclopropylmethyl, and Y is as defined above;

(XIX) is alkylated, alkenylated, arylalkylated or arylalkenylated, giving a compound according to formula (XX) wherein R1 is allyl or cyclopropylmethyl, R2 is as defined above in formula (XVI) and Y is also as defined above; and xxi) (XX) is hydrolized giving a compound according to formula (XVII), which in turn is converted to a compound according to formula (I) wherein R1 is allyl or cyclopropylmethyl, R3 is H and X is NH or O, exactly as described for the 5-substituted analogues.

74. The process of claim 73, wherein, in step xvii), the solvent is N,N-dimethylformamide or dichloromethane.

75. The process of claim 73, wherein, in step xvii), the strong base is sodium hydroxide, potassium hydroxide or sodium amide.

76. The process of claim 73, wherein, in step xvii), the diluted acid is hydrochloric acid or sulfuric acid.